Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Quick Links Investor Presentation Responsibility News Portfolio Responsibility Report Annual Reports Leadership Governance SEC Filings Latest Press Releases December 17, 2024 Incyte to Present at Upcoming Investor Conference December 10, 2024 Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma December 7, 2024 Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer All press releases Latest Events Jan 13 2025 Jan 13 2025 J. P .Morgan Healthcare Conference Click here for Webcast Dec 12 2024 Dec 12 2024 Incyte Data Highlights from ASH 2024 Click here for Webcast All events
